Gr. Matzke et al., Nephrology pharmaceutical care preceptorship: A programmatic and clinical outcomes assessment, ANN PHARMAC, 34(5), 2000, pp. 593-599
OBJECTIVE: The University of Pittsburgh Nephrology Pharmaceutical Care Prec
eptorship (NPCP) program was conceived to acquaint health system pharmacist
s with the pharmacotherapeutic management of dialysis patients, enhance the
delivery of pharmaceutical care, and improve clinical outcomes through the
development of specialized professional skills. A survey designed to deter
mine the impact of the NPCP program was sent to all 145 participants of the
program.
METHODS: The survey, designed to collect demographic information and data a
bout the participants' practice sites, professional activities prior to and
after the completion of the program, and markers of disease status, was ma
iled to all participants in September 1997. The 96 respondents (66.2%) were
involved in a wide variety of clinical practices; inpatient management of
peritoneal dialysis, hemodialysis, or renal transplant patients were most c
ommonly reported.
RESULTS: More than 80% of the participants believed that the educational co
ntent of the NPCP program was sufficient to allow them to establish a speci
alized service for the management of dialysis patients. However, two-thirds
would have preferred to have more contact time (an additional 1-2 d) with
the preceptorship faculty. The percentage of the pharmacists' time devoted
to the provision of pharmaceutical care for dialysis patients almost double
d, from 13.1% to 25.2% (p < 0.001). The components of pharmaceutical care p
erformed by these pharmacists also changed as a result of their completion
of the NPCP program. Time devoted to clinical services and the provision of
educational programs (inservices) increased significantly, while the time
allocated to distributive activities decreased from a mean of 32.4% to 26.4
% (almost 20% from baseline). The number of pharmacists who provided some c
omponent of pharmaceutical care for ambulatory dialysis patients increased
significantly, from 10 to 33, after completion of the program. In the surve
y given after the preceptorship, almost 70% of these 33 pharmacists self-re
ported that the mean hematocrit of their ambulatory dialysis patients incre
ased; 45% reported that the epoetin dose was lower. Parenteral iron use was
also reported to have increased in 78.8% of the dialysis units, and an inc
rease in serum ferritin and transferrin saturation was observed in 54.5% an
d 60.6% of the units, respectively. Although far fewer pharmacists (n = 15)
initiated a renal osteodystrophy management program, 73.3% of those who di
d so reported an increase in their patients' compliance with phosphate bind
er therapy, which was reflected in a drop in serum phosphorous in 40% of th
e units.
CONCLUSIONS: The NPCP program resulted in changes in the professional activ
ities of the participants: fewer distributive activities and increased clin
ical and educational activities. These significant changes were noted in al
l areas of outpatient care. Participation in the NPCP program enhanced the
delivery of pharmaceutical care to dialysis patients and improved the marke
rs of disease status.